{"id":"W2134091333","doi":"10.1186/1465-9921-12-156","title":"Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial","year":2011,"lang":"en","type":"article","venue":"Respiratory Research","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Tobacco Research Unit; University of Toronto","funders":"Novartis Pharma; GlaxoSmithKline; AstraZeneca","keywords":"Medicine; COPD; Placebo; Bronchodilator; Tiotropium bromide; Tolerability; Internal medicine; Vital capacity; Anesthesia; Ipratropium bromide; Randomized controlled trial; Spirometry; Asthma; Adverse effect; Lung; Lung function","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007988791,0.0007699868,0.002118351,0.000175398,0.0002614273,0.0009582817,0.0006558847,0.001133036,0.003137655],"category_scores_gemma":[0.0007171455,0.0002371957,0.001232557,0.0001926398,0.0004704027,0.0004181909,0.0003215208,0.001610878,0.0006935169],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004622972,"about_ca_system_score_gemma":0.000617073,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006524166,"about_ca_topic_score_gemma":0.0018106,"domain_scores_codex":[0.9996699,0.0001621165,0.00002055149,0.00005472642,0.00003589532,0.00005688016],"domain_scores_gemma":[0.9995111,0.00007993792,0.000122513,0.00003381261,0.00003107795,0.0002215601],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9131187,0.004198747,0.004895843,0.001614241,0.002545957,0.000139045,0.0001127375,0.0004825823,0.01138603,0.0001649826,0.003608106,0.05773304],"study_design_scores_gemma":[0.8352198,0.1212783,0.03496996,0.0002654165,0.001663424,0.0003713512,0.0001286471,0.000655058,0.001549558,0.0004037599,0.003429904,0.00006472396],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859104,0.01076441,0.00008092601,0.0005586494,0.0001392917,0.000411284,0.0007840327,0.00004901791,0.001302046],"genre_scores_gemma":[0.9933164,0.002816483,0.0001807955,0.0007759572,0.000176151,0.0005510545,0.0008377589,0.00001076691,0.001334593],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003137655,"threshold_uncertainty_score":0.0104965,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08327086123733947,"score_gpt":0.348145709231048,"score_spread":0.2648748479937085,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}